Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing disorders, announces that it has received approval for its Clinical Trial Application to initiate a Phase 1/2 clinical trial of SENS-501, in France.
